Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Points to Consider Response with Clinical Protocol, July 6, 1990

1 Oct 1990

Abstract excerpt

SCIENTIFIC ABSTRACT Severe combined immunodeficiency (SCID) due to deficiency of the purine metabolic enzyme adenosine deaminase (ADA) is a fatal childhood immunodeficiency disease. Immune reconstitution by transplantation with HLA-identical bone marrow is the treatment of choice. For patients not candidates for bone marrow transplantation, we propose to attempt immune reconstitution by using infusions of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Immunodeficiency and Autoimmune Disorders
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 11642817
DOI: 10.1089/hum.1990.1.3-331

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Points to Consider Response with Clinical Protocol, July 6, 1990PMID 11642817Read ↗

How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID)Semantic proximity Read ↗

Treatment of Severe Combined Immunodeficiency Disease (SCID) due to Adenosine Deaminase Deficiency with CD34 <sup>+</sup> Selected Autologous Peripheral Blood Cells Transduced with a Human ADA Gene (Amendment). National Institutes of HealthSemantic proximity Read ↗

T Lymphocyte-Directed Gene Therapy for ADA <sup>−</sup> SCID: Initial Trial Results After 4 YearsSemantic proximity Read ↗

Management Dilemma in Choosing Evolving Treatments in Neutropenic Septic ShockSemantic proximity Read ↗

[Gene therapy for adenosine deaminase deficiency].Semantic proximity Read ↗

Tests for Probability of A Reaction and Difference Between Reactions Where Treatment Increases Marker-Values of Particular Subjects but Decreases OthersSemantic proximity Read ↗

Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.Semantic proximity Read ↗

Efficacy and safety of donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation in pediatric patientsSemantic proximity Read ↗

Successful Peripheral T-Lymphocyte–Directed Gene Transfer for a Patient With Severe Combined Immune Deficiency Caused by Adenosine Deaminase DeficiencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.